Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 1,801–1,900 of 15,747
Fraley, E., LeMaster, C., Geanes, E. S., Banerjee, D., Khanal, S., Grundberg, E., Selvarangan, R., & Bradley, T. (2021) · BMC Medicine · doi:10.1186/s12916-021-02055-9 · Cited by 65
Khairallah, P., Aggarwal, N., Awan, A. A., Vangala, C., Airy, M., Pan, J. S.-C., Murthy, B. V. R., Winkelmayer, W. C., & Ramanathan, V. (2021) · Transplant International · doi:10.1111/tri.13840 · Cited by 74
RNA modification in mRNA cancer vaccines
Mei, Y., & Wang, X. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01020-5 · Cited by 62
COVAX-19Ⓡ Vaccine: Completely blocks virus transmission to non-immune individuals
Chavda, V. P., Vora, L. K., & Vihol, D. R. (2021) · Clinical Complementary Medicine and Pharmacology · doi:10.1016/j.ccmp.2021.100004 · Cited by 65
SARS‐CoV‐2 and its variants of concern including Omicron: A never ending pandemic
Mohapatra, R. K., Kuppili, S., Suvvari, T. K., Kandi, V., Behera, A., Verma, S., Kudrat‐E‐Zahan, Biswal, S. K., AL-Noor, T. H., El‐ajaily, M. M., et al. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14035 · Cited by 64
SARS-CoV-2 Vaccination — An Ounce (Actually, Much Less) of Prevention
Rubin, E. J., & Longo, D. L. (2020) · New England Journal of Medicine · doi:10.1056/nejme2034717 · Cited by 66
Dreyer-Alster, S., Menascu, S., Mandel, M., Shirbint, E., Magalashvili, D., Dolev, M., Flechter, S., Givon, U., Guber, D., Stern, Y., et al. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120155 · Cited by 60
Antigenic characterization of influenza and SARS-CoV-2 viruses
Wang, Y., Tang, C. Y., & Wan, X. (2021) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03806-6 · Cited by 73
“The success of these vaccines is attributed to the use of nucleoside-modified mRNA to enhance translation capacity and reduce the innate immunity response and the unique use of lipid nanoparticles (LNPs) to improve mRNA stability and cellular penetration [454, 455].”
BackgroundVaccination in Chronic Liver Disease: An Update
Alukal, J. J., Naqvi, H. A., & Thuluvath, P. J. (2021) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2021.12.003 · Cited by 71
Funk, C. D., Laferrière, C. A., & Ardakani, A. (2021) · Viruses · doi:10.3390/v13030418 · Cited by 61
Vaccine-Associated Uveitis after COVID-19 Vaccination
Singh, R. B., Parmar, U. P. S., Kahale, F., Agarwal, A. K., & Tsui, E. Y. K. (2022) · Ophthalmology · doi:10.1016/j.ophtha.2022.08.027 · Cited by 63
Durability of immune responses to the BNT162b2 mRNA vaccine
Suthar, M. S., Arunachalam, P. S., Hu, M., Reis, N., Trisal, M., Raeber, O., Chinthrajah, R. S., Davis-Gardner, M. E., Manning, K. E., Mudvari, P., et al. (2022) · Med · doi:10.1016/j.medj.2021.12.005 · Cited by 66
Hayawi, K., Shahriar, S., Serhani, M. A., Alashwal, H., & Masud, M. M. (2021) · Vaccines · doi:10.3390/vaccines9111305 · Cited by 62
“Early clinical trials for many vaccines were reported to be highly effective against the reference SARS-CoV-2 variant [4,5] and more than 5 billion vaccine doses have been administered by 31 August 2021 [1].”
BackgroundGuillain-Barré syndrome following BNT162b2 COVID-19 vaccine
Trimboli, M., Zoleo, P., Arabia, G., & Gambardella, A. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05523-5 · Cited by 64
Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines
Mouro, V., & Fischer, A. (2022) · Mucosal Immunology · doi:10.1038/s41385-022-00517-8 · Cited by 61
Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans
Young-Xu, Y., Korves, C., Roberts, J., Powell, E. I., Zwain, G. M., Smith, J., & Izurieta, H. S. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.28391 · Cited by 58
Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization
Sui, Y., Bekele, Y., & Berzofsky, J. A. (2021) · Pathogens · doi:10.3390/pathogens10020138 · Cited by 60
Nanomaterials‐Mediated Co‐Stimulation of Toll‐Like Receptors and CD40 for Antitumor Immunity
Yan, J., Zhang, Y., Du, S., Hou, X., Li, W., Zeng, C., Zhang, C., Cheng, J. K. J., Deng, B., McComb, D. W., et al. (2022) · Advanced Materials · doi:10.1002/adma.202207486 · Cited by 63
Luo, D. Y., Zhou, J., Ruan, S., Zhang, B., Zhu, H., Que, Y., Ying, S., Li, X., Hu, Y., & Song, Z. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07385-7 · Cited by 79
Prophylactic HIV-1 vaccine trials: past, present, and future
Nkolola, J. P., & Barouch, D. H. (2023) · The Lancet HIV · doi:10.1016/s2352-3018(23)00264-3 · Cited by 72
Wang, Y. X., Zhang, J., Liu, Y., Xiao, Y., Han, K. S., Kong, Z., Dong, Y., Yang, Z., Fu, Z., Tang, C., et al. (2024) · Science Advances · doi:10.1126/sciadv.ado4791 · Cited by 82
“Lipid nanoparticles (LNPs) have been considered as a well-established nonviral nanocarrier for gene therapy with the clinical successes of mRNA-based COVID-19 vaccines ( 34 – 36 ).”
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
(2022) · doi:10.1101/2022.08.07.499047 · Cited by 59
Inhibition of SARS-CoV-2 coronavirus proliferation by designer antisense-circRNAs
Pfafenrot, C., Schneider, T. P., Müller, C., Hung, L.-H., Schreiner, S., Ziebuhr, J., & Bindereif, A. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1096 · Cited by 60
“and mRNA-based vaccines) are being developed and tested, many of which providing promising new approaches to prevent or treat COVID-19 more effectively (9).”
SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question
Marjot, T., Webb, G. J., Barritt, A. S., Ginès, P., Lohse, A. W., Moon, A. M., Pose, E., Trivedi, P. J., & Barnes, E. J. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00008-x · Cited by 59
Next RNA Therapeutics: The Mine of Non-Coding
Garbo, S., Maione, R., Tripodi, M., & Battistelli, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137471 · Cited by 62
“The importance of the development of the two mRNA-based vaccines against COVID-19, mRNA-1273 (Moderna) [88], and BNT162b2 (Pfizer-BioNTech) [89], during these years represents the potentiality of the RNA-based therapy.”
BackgroundUniversal Barcoding Predicts In Vivo ApoE-Independent Lipid Nanoparticle Delivery
Sanchez, A. J. D. S., Dobrowolski, C. N., Cristian, A., Echeverri, E. S., Zhao, K., Hatit, M. Z. C., Loughrey, D., Paunovska, K., & Dahlman, J. E. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c01133 · Cited by 66
Netti, G. S., Infante, B., Troise, D. E., Mercuri, S., Panico, M., Spadaccino, F., Catalano, V., Gigante, M., Simone, S., Pontrelli, P., et al. (2022) · American Journal of Transplantation · doi:10.1111/ajt.16958 · Cited by 67
Development and preclinical evaluation of virus‐like particle vaccine against COVID‐19 infection
Yilmaz, I. C., İpekoğlu, E. M., Bulbul, A., Turay, N., Yıldırım, M., Evcili, İ., Yilmaz, N. S., Guvencli, N., Aydin, Y., Gungor, B., et al. (2021) · Allergy · doi:10.1111/all.15091 · Cited by 66
Nachtigall, I., Bonsignore, M., Hohenstein, S., Bollmann, A., Günther, R., Kodde, C., Englisch, M., Ahmad‐Nejad, P., Schröder, A., Glenz, C., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07284-8 · Cited by 62
Lotan, I., Wilf‐Yarkoni, A., Friedman, Y., Stiebel‐Kalish, H., Steiner, I., & Hellmann, M. A. (2021) · European Journal of Neurology · doi:10.1111/ene.15028 · Cited by 59
Benning, L., Töllner, M., Hidmark, Å. S., Schaier, M., Nußhag, C., Kälble, F., Reichel, P., Buylaert, M., Grenz, J., Ponath, G. D., et al. (2021) · Vaccines · doi:10.3390/vaccines9080857 · Cited by 63
“Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine as well as of the chimpanzee adenovirus-vectored vaccine ChAdOx1 nCoV-19 have been described in great detail for homologous prime-boost vaccination [1,2].”
BackgroundGoel, R. R., Painter, M. M., Apostolidis, S. A., Mathew, D., Meng, W., Rosenfeld, A. M., Lundgreen, K. A., Reynaldi, A., Khoury, D. S., Pattekar, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.23.457229 · Cited by 59
“Community-level immunity, acquired through natural infection or vaccination, is necessary to control the pandemic as the virus continues to circulate ( 1 ). mRNA vaccines encoding a stabilized version of the full-length SARS-CoV-2 Spike protein are being widely administered and clinical trial data demonstrate up to 95…”
MethodInfluentialCRISPR–Cas9 delivery strategies for the modulation of immune and non-immune cells
Alsaiari, S. K., Eshaghi, B., Du, B., Kanelli, M., Li, G., Wu, X., Zhang, L., Chaddah, M., Lau, A., Yang, X., et al. (2024) · Nature Reviews Materials · doi:10.1038/s41578-024-00725-7 · Cited by 70
VILCHES, T. N., Nourbakhsh, S., Zhang, K., Juden-Kelly, L., Cipriano, L. E., Langley, J. M., Sah, P., Galvani, A. P., & Moghadas, S. M. (2021) · Preventive Medicine · doi:10.1016/j.ypmed.2021.106564 · Cited by 68
Glampson, B., Brittain, J., Kaura, A., Mulla, A., Mercuri, L., Brett, S. J., Aylin, P. P., Sandall, T., Goodman, I., Redhead, J., et al. (2021) · JMIR Public Health and Surveillance · doi:10.2196/30010 · Cited by 69
Reasons for success and lessons learnt from nanoscale vaccines against COVID-19
Kisby, T., Yılmazer, A., & Kostarelos, K. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00946-9 · Cited by 68
Covid-19 vaccines: delivering protective immunity
Sewell, H. F., Agius, R. M., Kendrick, D., & Stewart, M. (2020) · BMJ · doi:10.1136/bmj.m4838 · Cited by 62
Poukka, E., Baum, U., Palmu, A. A., Lehtonen, T. O., Salo, H., Nohynek, H., & Leino, T. (2022) · Vaccine · doi:10.1016/j.vaccine.2021.12.032 · Cited by 58
“Covid-19 vaccines have been highly efficacious [1, 2].”
Powell, A. A., Power, L., Westrop, S., McOwat, K., Campbell, H., Simmons, R., Ramsay, M. E., Brown, K., Ladhani, S. N., & Amirthalingam, G. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.28.2100634 · Cited by 58
Supabphol, S., Li, L., Goedegebuure, S. P., & Gillanders, W. E. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1896702 · Cited by 64
Morales‐Núñez, J. J., Muñóz-Valle, J. F., Meza-López, C., Wang, L., Machado-Sulbarán, A. C., Torres-Hernández, P. C., Bedolla‐Barajas, M., la O-Gómez, B. D., Balcázar-Félix, P., & Hernández‐Bello, J. (2021) · Vaccines · doi:10.3390/vaccines9070742 · Cited by 56
“The vaccinated group with prior COVID-19 presented more side effects in both vaccine doses; this is consistent with other studies [6,15,22].”
BackgroundResultCanaday, D. H., Oyebanji, O. A., White, E. M., Keresztesy, D., Payne, M., Wilk, D. J., Carias, L. L., Aung, H., Denis, K. S., Sheehan, M. L., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104066 · Cited by 61
Impact of vaccination and non-pharmaceutical interventions on SARS-CoV-2 dynamics in Switzerland
Shattock, A. J., Rutte, E. A. L., Dünner, R. P., Sen, S., Kelly, S. L., Chitnis, N., & Penny, M. A. (2021) · Epidemics · doi:10.1016/j.epidem.2021.100535 · Cited by 69
Can reactogenicity predict immunogenicity after COVID-19 vaccination?
Hwang, Y. H., Song, K., Choi, Y., Go, S., Choi, S., Jung, J., Kang, C. K., Choe, P. G., Kim, N. J., Park, W. B., et al. (2021) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2021.210 · Cited by 59
“In the case of SARS-CoV-2 vaccination, previous studies reported that BNT162b2 is less reactogenic and immunogenic in an older population consistent with the current study, but the humoral response after two doses exceeds that in convalescent serum [4,11].”
BackgroundResultImmunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency
Arroyo‐Sánchez, D., Cabrera-Marante, Ó., Laguna‐Goya, R., Almendro-Vázquez, P., Carretero, O., Gil‐Etayo, F. J., Suàrez-Fernández, P., Pérez‐Romero, P., de Frías, E. R., Serrano, A., et al. (2021) · Journal of Clinical Immunology · doi:10.1007/s10875-021-01174-5 · Cited by 64
Dézsi, L., Mészáros, T., Kozma, G. T., H-Velkei, M., Oláh, C. Z., Szabó, M., Patkó, Z., Fülöp, T., Hennies, M., Szebeni, M., et al. (2022) · GeroScience · doi:10.1007/s11357-021-00495-y · Cited by 62
“Beyond efficacy, a major contributor to the success of COVID-19 vaccines, including Pfizer/BioNTech’s BNT162b2, an mRNA-lipid nanoparticle (mRNA-LNP)-based vaccine also called Comirnaty (CMT), is their safety in the overwhelming majority of vaccinated people [1].”
BackgroundAn mRNA-based T-cell-inducing antigen strengthens COVID-19 vaccine against SARS-CoV-2 variants
Tai, W., Feng, S., Chai, B., Lu, S., Zhao, G., Chen, D., Yu, W., Ren, L., Shi, H., Lü, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38751-8 · Cited by 60
Endosomal sorting results in a selective separation of the protein corona from nanoparticles
Han, S., Marques, R. D. C., Simon, J., Kaltbeitzel, A., Koynov, K., Landfester, K., Mailänder, V., & Lieberwirth, I. (2023) · Nature Communications · doi:10.1038/s41467-023-35902-9 · Cited by 66
Machine Learning‐Enhanced Nanoparticle Design for Precision Cancer Drug Delivery
Wang, Q., Liu, Y., Li, C., Xu, S., Xu, S., & Liu, B. (2025) · Advanced Science · doi:10.1002/advs.202503138 · Cited by 103
Principles of lipid nanoparticle design for mRNA delivery
Zhang, Y., Zhang, X., Gao, Y., & Liu, S. (2024) · BMEMat · doi:10.1002/bmm2.12116 · Cited by 71
Side Effects of COVID-19 Pfizer-BioNTech mRNA Vaccine in Children Aged 12–18 Years in Saudi Arabia
Alamer, E., Alhazmi, A., Qasir, N. A., Alamer, R. A., Areeshi, H., Gohal, G. A., Qadri, M. M., Hashem, A. M., & Algaissi, A. A. (2021) · Vaccines · doi:10.3390/vaccines9111297 · Cited by 57
“More side effects have been reported by the younger population compared to their older counterparts [37,38].”
BackgroundThe mRNA-LNP vaccines – the good, the bad and the ugly?
Igyártó, B. Z., & Qin, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1336906 · Cited by 71
Monoclonal antibody levels and protection from COVID-19
Stadler, E., Burgess, M. T., Schlub, T. E., Khan, S. R., Chai, K. L., McQuilten, Z., Wood, E. M., Polizzotto, M. N., Kent, S. J., Cromer, D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40204-1 · Cited by 65
Current progress in the development of prophylactic and therapeutic vaccines
Li, T., Qian, C., Gu, Y., Zhang, J., Li, S., & Xia, N. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2230-4 · Cited by 63
“S) (Baden et al., 2020; Polack et al., 2020) against the COVID19 pandemic have been the quickest vaccines ever developed.”
BackgroundTamari, R., Politikos, I., Knorr, D. A., Vardhana, S. A., Young, J. C., Marcello, L. T., Doddi, S., Devlin, S. M., Ramanathan, L. V., Pessin, M. S., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0142 · Cited by 55
Faster than warp speed: early attention to COVD-19 by anti-vaccine groups on Facebook
Kalichman, S. C., Eaton, L. A., Earnshaw, V. A., & Brousseau, N. M. (2021) · Journal of Public Health · doi:10.1093/pubmed/fdab093 · Cited by 68
Sugawara, N., Yasui‐Furukori, N., Fukushima, A., & Shimoda, K. (2021) · Vaccines · doi:10.3390/vaccines9111295 · Cited by 59
Does mRNA SARS-CoV-2 vaccine detrimentally affect male fertility, as reflected by semen analysis?
Lifshitz, D., Haas, J., Lebovitz, O., Raviv, G., Orvieto, R., & Aizer, A. (2021) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2021.09.021 · Cited by 60
Bradley, B. T., Bryan, A. B., Fink, S. L., Goecker, E. A., Roychoudhury, P., Huang, M.-L. W., Zhu, H., Chaudhary, A., Madarampalli, B., Lu, J., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00989-21 · Cited by 56
“Although phase III vaccine trials demonstrated excellent efficacies among treated populations (12, 13), a number of subpopulations, including pregnant women and immunocompromised individuals, were excluded from these trials.”
BackgroundAl-Maqbali, J. S., Rasbi, S. A., Kashoub, M. S., Hinaai, A. M. A., Farhan, H., Rawahi, B. A., & Alawi, A. M. A. (2021) · American Journal of Case Reports · doi:10.12659/ajcr.932946 · Cited by 63
“Other ADRs were mild to moderate local or systematic reactions [6].”
BackgroundRénia, L., Goh, Y. S., Rouers, A., Bert, N. L., Chia, W. N., Chavatte, J., Fong, S., Chang, Z. W., Zhuo, N. Z., Tay, M. Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32312-1 · Cited by 69
“Sample distribution showed that low responders tended to cluster by age into two categories (1) <60 and (2) ≥60 years.”
BackgroundKerr, S., Joy, M., Torabi, F., Bedston, S., Akbari, A., Agrawal, U., Beggs, J., Bradley, D., Chuter, A., Docherty, A. B., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1003927 · Cited by 62
Rubinstein, T. J. (2021) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000002059 · Cited by 58
Wu, X., Wang, L., Shen, L., & Tang, K. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104102 · Cited by 63
Selma‐Royo, M., Bäuerl, C., Tudela, D. M., Aguilar‐Camprubí, L., Pérez-Cano, F. J., Llorca, A. P., Lerín, C., Martínez‐Costa, C., & Collado, M. C. (2022) · Genome Medicine · doi:10.1186/s13073-022-01043-9 · Cited by 67
Jedicke, N., Stankov, M. V., Cossmann, A., Dopfer‐Jablonka, A., Knuth, C., Ahrenstorf, G., Ramos, G. M., & Behrens, G. M. N. (2021) · HIV Medicine · doi:10.1111/hiv.13202 · Cited by 71
mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates
Corbett, K. S., Werner, A. P., Connell, S. O., Gagne, M., Lai, L., Moliva, J. I., Flynn, B., Choi, A., Koch, M., Foulds, K. E., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01021-0 · Cited by 57
Wagner, A., Garner‐Spitzer, E., Schötta, A., Orola, M. J., Wessely, A., Zwazl, I., Ohradanova‐Repic, A., Weseslindtner, L., Tajti, G., Gebetsberger, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.889138 · Cited by 61
“These vaccines have been shown to be highly immunogenic in healthy individuals (3, 4).”
BackgroundHertel, M., Heiland, M., Nahles, S., von Laffert, M., Mura, C., Bourne, P. E., Preißner, R., & Preißner, S. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18184 · Cited by 68
Zhou, W., Jiang, L., Liao, S., Wu, F., Yang, G., Hou, L., Liu, L., Pan, X., Jia, W. W.-G., & Zhang, Y. (2023) · Viruses · doi:10.3390/v15081760 · Cited by 70
“Furthermore, in response to the SARS-CoV-2 pandemic, mRNA-based COVID-19 vaccines were granted emergency authorization by the FDA in 2020, effectively safeguarding individuals against SARS-CoV2 infection.”
BackgroundInfluentialGurion, R., Rozovski, U., Itchaki, G., Gafter‐Gvili, A., Leibovitch, C., Raanani, P., Ben‐Zvi, H., Szwarcwort, M., Taylor-Abigadol, M., Dann, E. J., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.279216 · Cited by 59
“No anti-CD20 therapy 56 45 80 (68-90) 20 (10-32)”
Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis
Schrezenmeier, E. V., Bergfeld, L., Hillus, D., Lippert, J.-D., Weber, U., Tober‐Lau, P., Landgraf, I., Schwarz, T., Kappert, K., Stefanski, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690698 · Cited by 61
Goletti, D., Petrone, L., Manissero, D., Bertoletti, A., Rao, S. N., Ndunda, N., Sette, A., & Nikolayevskyy, V. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.07.005 · Cited by 78
“As the protective effect of vaccination has been observed from day 12 post-administration [39], it is likely that T cells play an important early role in vaccine-mediated immunity [43,46].”
Cairns, D. M., Dulko, D., Griffiths, J. K., Golan, Y., Cohen, T., Trinquart, L., Price, L. L., Beaulac, K. R., & Selker, H. P. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.44942 · Cited by 57
Buske, C., Dreyling, M. H., Álvarez‐Larrán, A., Apperley, J. F., Arcaini, L., Besson, C., Bullinger, L., Corradini, P., Porta, M. G. D., Dimopoulos, M. A., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100403 · Cited by 66
“100403 Currently, there are efficient vaccines for immunocompetent individuals, licensed against COVID-19.(44-46) Generally, vaccines work in patients with HMs with immune(47) and clinical responses(48-50) and are currently generally recommended.”
Karunakaran, B., Gupta, R., Patel, P., Salave, S., Sharma, A. K., Desai, D. N., Benival, D. M., & Kommineni, N. (2023) · Vaccines · doi:10.3390/vaccines11030661 · Cited by 70
“1% (mRNA-1273) in clinical trials [7,8].”
Polatoğlu, İ., Öner, T. Ö., Dalman, I., & Ozdogan, S. (2023) · MedComm · doi:10.1002/mco2.228 · Cited by 90
Kang, C. K., Kim, M., Lee, S., Kim, G., Choe, P. G., Park, W. B., Kim, N. J., Lee, C., Kim, I. S., Jung, K., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab159 · Cited by 63
SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency: Findings from the COV-AD Study
Shields, A. M., Faustini, S. E., Hill, H. J., Al‐Taei, S., Tanner, C., Ashford, F. B., Workman, S., Moreira, F., Verma, N., Wagg, H., et al. (2022) · Journal of Clinical Immunology · doi:10.1007/s10875-022-01231-7 · Cited by 66
Bahnan, W., Wrighton, S., Sundwall, M., Bläckberg, A., Larsson, O. J., Höglund, U., Khakzad, H., Godzwon, M., Walle, M., Elder, E. E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.808932 · Cited by 62
Modeling COVID-19 dynamic using a two-strain model with vaccination
de León, U. A.-P., Avila-Vales, E. J., & Huang, K. (2022) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2022.111927 · Cited by 62
Age-related heterogeneity in immune responses to SARS-CoV-2 vaccine BNT162b2
(2021) · doi:10.1101/2021.02.03.21251054 · Cited by 750
Structural Basis for SARS-CoV-2 Nucleocapsid Protein Recognition by Single-Domain Antibodies
Ye, Q., Lu, S., & Corbett, K. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.719037 · Cited by 57
“Despite the development and widespread use of effective vaccines against SARS-CoV-2 (Polack et al., 2020;Baden et al., 2021;Sadoff et al., 2021), the virus and its emerging variants will remain an active public health threat for the foreseeable future.”
Ishii, H., Nomura, T., Yamamoto, H., Nishizawa, M., Hau, T. T. T., Harada, S., Seki, S., Nakamura‐Hoshi, M., Okazaki, M., Daigen, S., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100520 · Cited by 63
(2021) · doi:10.1101/2021.04.06.21254963 · Cited by 57
“11 Discussion Based on large phase III clinical trials (7) and access to health care institution recordings (10), tremendous data sets are available suggesting high efficacy of SARS-CoV2 vaccine BNT162b2 in preventing severe or fatal COVID-19 even in individuals with comorbidities or advanced age.”
BackgroundCOVID-19: Insights into Potential Vaccines
Loo, K.-Y., Letchumanan, V., Ser, H., Teoh, S. L., Law, J. W., Tan, L. T., Mutalib, N. A., Chan, K., & Lee, L. (2021) · Microorganisms · doi:10.3390/microorganisms9030605 · Cited by 62
Du, S., Li, W., Zhang, Y., Xue, Y., Hou, X., Yan, J., Cheng, J. K. J., Deng, B., McComb, D. W., Lin, J. S., et al. (2023) · Advanced Science · doi:10.1002/advs.202300188 · Cited by 66
A chitosan-mediated inhalable nanovaccine against SARS-CoV-2
Zhuo, S., Wu, J., Zhao, L., Li, W., Zhao, Y., & Li, Y. (2022) · Nano Research · doi:10.1007/s12274-021-4012-9 · Cited by 58
Agrati, C., Castilletti, C., Goletti, D., Meschi, S., Sacchi, A., Matusali, G., Bordoni, V., Petrone, L., Lapa, D., Notari, S., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9061315 · Cited by 64
“The vaccination strategy for the BNT162b2 vaccine involves a two-dose vaccination regimen administered 21 days apart, which has been demonstrated to induce a spike protein (S)-specific humoral and cellular immunity associated with a 95% efficacy in naïve individuals [1].”
BackgroundSix-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors
Waldhorn, I., Holland, R., Goshen‐Lago, T., Shirman, Y., Szwarcwort‐Cohen, M., Benaim, A. R., Shachor‐Meyouhas, Y., Hussein, K., Fahoum, L., Peer, A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1072 · Cited by 63
“High efficacy of the mRNA-based BNT162b2 vaccine against SARS-CoV-2 has been demonstrated in both a large clinical trial and reallife data in the general population (1, 4).”
BackgroundThomas, S. J., Perez, J. L., Lockhart, S. P., Hariharan, S., Kitchin, N. R. E., Bailey, R. E., Liau, K., Lagkadinou, E., Türeci, Ö., Şahin, U., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.12.046 · Cited by 67
Self-citationShapiro, J. R., Sitaras, I., Park, H. S., Aytenfisu, T. Y., Caputo, C. A., Li, M., Lee, J., Johnston, T. S., Li, H., Wouters, C., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac397 · Cited by 58
“(mRNA) vaccines (mRNA-1273 and BNT162b2) revealed high efficacy in older adults [4, 5], for whom immunosenescence is thought to impair vaccine-induced immune responses”
BackgroundCovid-19 vaccine and autoimmunity: Awakening the sleeping dragon
Akinosoglou, K., Tzivaki, I., & Marangos, M. N. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108721 · Cited by 57
Pham, M. N., Murugesan, K., Banaei, N., Pinsky, B. A., Tang, M. C., Hoyte, E. G., Lewis, D. B., & Gernez, Y. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.11.022 · Cited by 60
Acute Coronary Tree Thrombosis After Vaccination for COVID-19
Tajstra, M., Jaroszewicz, J., & Gąsior, M. (2021) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2021.03.003 · Cited by 57
Trougakos, I. P., Terpos, E., Zirou, C., Sklirou, A. D., Apostolakou, F., Gumeni, S., Charitaki, I., Papanagnou, E., Bagratuni, T., Liacos, C., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02090-6 · Cited by 61
“Among the first vaccines authorized for emergency use by both the FDA and EMA was the BNT162b2 mRNA vaccine due to its efficacy in healthy recipients [13].”
BackgroundSekiguchi, K., Watanabe, N., Miyazaki, N., Ishizuchi, K., Iba, C., Tagashira, Y., Uno, S., Shibata, M., Hasegawa, N., Takemura, R., et al. (2021) · Cephalalgia · doi:10.1177/03331024211038654 · Cited by 64
“There are three COVID-19 vaccines (5,10,11) in Japan as for July 2021, but at the time of survey, only the BNT162b2 vaccine was available.”
BackgroundClinical development of therapeutic mRNA applications
Żak, M. M., & Zangi, L. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.034 · Cited by 79
Parvin, N., Joo, S. W., & Mandal, T. K. (2024) · Biomolecules · doi:10.3390/biom14081036 · Cited by 77
“P fi zer-BioNTech and Moderna’s vaccines demonstrated high e ffi cacy rates of approximately 95% and 94%, respectively, in preventing symptomatic COVID-19 infection [4,5].”
Background33 Unresolved Questions in Nanoscience and Nanotechnology
Mirkin, C. A., Petrosko, S. H., Artzi, N., Aydın, K., Biaggne, A., Brinker, C. J., Bujold, K. E., Cao, Y. C., Chan, R. R., Chen, C., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c12854 · Cited by 69
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.